SANOFI requested the U.S. Food and Drug Administration remove its diabetes drug Tzield from a fast-track review program following internal regulatory disputes. The move follows a disagreement between leadership and staff at the FDA over the drug's safety profile for younger patients. Investors face potential delays in Tzield's expansion as safety data comes under renewed scrutiny in the United States.

Regulatory Friction Over Tzield Safety